preloader
preloader

Harnessing AI for Strategic Market Assessment Post-LOE in 2025

  • Client

    A leading pharmaceutical company specializing in anti-infective treatments, with a key product facing Loss of Exclusivity (LOE) in 2025. The client operates in both hospital and retail segments and sought advanced, data-driven strategies to sustain market share and profitability post-LOE.
  • Primary Goal

    Conduct a comprehensive market analysis post-LOE to evaluate competitors, pricing shifts, and buyer behavior, leveraging AI-driven insights for analog selection, strategic positioning, and resource optimization to safeguard market share, maintain pricing integrity, and enhance decision-making efficiency.

  • Vamstar Capability

    • Enhanced Insights

    • AI Price Optimization

    • Competitor Analysis

    • Margins Protection

Introduction

Facing the 2025 Loss of Exclusivity (LOE) for a flagship anti-infective product, a leading pharmaceutical company required robust insights into post-LOE market dynamics. The product, a vital treatment sold across hospital and retail segments, faced significant pricing and competitive pressures.

 

Vamstar employed its proprietary AI to analyze market trends, competitor strategies, and buyer behaviors. This involved leveraging vast datasets and AI algorithms to provide actionable strategic options and defend market share effectively.

 

The client expected precise, data-backed recommendations to mitigate risks, optimize resource allocation, and refine competitive strategies, ensuring sustained profitability and market presence.

Key outcomes

  • Enhanced Insights: Comprehensive post-LOE market analysis

  • AI Optimization: Precision in pricing and strategy modeling

  • Competitor Analysis: Identification of key threats and opportunities

  • Resource Efficiency: Data-driven allocation of commercial efforts

  • Sustained Margins: Minimized erosion through strategic pricing

Transformation Journey

  • Before Vamstar
  • During Vamstar’s Involvement
  • After Vamstar

The pharmaceutical company struggled with an outdated approach to market assessment, relying heavily on traditional consulting firms that delivered limited, human-driven analyses. These narrow assessments lacked scalability, depth, and the power of real-time data, leaving the company with fragmented market intelligence and analog selection processes driven more by subjective judgment than comprehensive insights.

As a result, inefficiencies plagued the company’s competitive strategy. Analog selection was slow and reactive, often missing critical market signals and failing to reflect real-world dynamics. With insights arriving too late to influence strategy, the company remained vulnerable to pricing pressures, competitive threats, and rapid market shifts—particularly in post-LoE (Loss of Exclusivity) scenarios, where pricing erosion was swift and severe.

The absence of predictive analytics compounded these challenges, leaving the company with a critical strategic blind spot. Without forward-looking insights, they were unable to anticipate competitor moves, model future pricing scenarios, or seize new market opportunities. This lack of data-driven foresight weakened their ability to address post-LoE challenges and threatened their ability to sustain market leadership in an increasingly competitive landscape.

Harness AI to drive growth

Take a step towards improving your commercial operations. Register today.